Quarterly ResultAug 13, 2026, 04:45 PM
VolitionRx Q2 Revenue $0.4M; Operating Loss Down 34%
AI Summary
VolitionRx Limited announced its second quarter 2026 financial results and business updates. The company reported Q2 revenue of $0.4 million, in line with the prior year, while significantly reducing operating expenses by 32% and operating loss by 34% to $4.2 million. First half 2026 revenue saw substantial growth of 112% to $1.4 million. Key business developments include a collaboration with Sysmex, submission of a clinical manuscript for its feline lymphoma assay with a potential $5 million milestone, and ongoing discussions for licensing agreements. A conference call to discuss these results is scheduled for August 14, 2026.
Key Highlights
- Q2 2026 revenue was $0.4 million, consistent with the same period in 2025.
- Operating expenses for Q2 2026 decreased by 32% compared to Q2 2025.
- Operating loss for Q2 2026 was $4.2 million, a 34% reduction from Q2 2025.
- Net cash used in operating activities for Q2 2026 was $5.2 million, 18% lower year-over-year.
- First half 2026 revenue grew 112% to $1.4 million over the first half of 2025.
- Received $1.2 million in net proceeds from equity sales and $4.1 million from a public offering.
- Submitted a clinical manuscript for Nu.Q® Vet feline assay, potentially unlocking a $5 million milestone payment.
- Announced a collaboration with Sysmex Corporation and is pursuing licensing agreements.
Price Impact
More from VNRX